Drug industry
Article Abstract:
The pharmaceutical industry research-oriented giants produced double digit earnings for the March quarter of 1997 and their stocks performed reasonably well, considering the tumultuous stock market conditions. However, the small company sector of the industry, which performed poorly in 1996, showed abysmal results for the first four months of 1997. Although the large pharmaceutical industry has high Timeliness and Safety ratings, their stocks carry high prices and offer poor 3- to 5-year appreciation potential.
Author: Clark, Charles, Butler, Jeremy J., Markey, Keith A., Ferguson, Keith E., Rho, George I.H., Maher, John E.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1997
Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Biological Product (except Diagnostic) Manufacturing, Drugs, Generic Drugs, Biochemicals, Biotechnology industry, Biotechnology industries, Chemicals, Biological products, Pharmacia and Upjohn Inc., PNU, SmithKline Beecham PLC, Cygnus Inc., Dura Pharmaceuticals Inc., Watson Pharmaceuticals Inc., AMGN, DURA, MLY, PRGO, Neurex Corp., SHR, WATS
Drug industry
Article Abstract:
Sales and profits for US drug companies were strong in the 1st qtr of 1995. The weak dollar helped since 40% to 50% of drug revenues come from foreign markets. The Republican Congress, elected in 1994, will end President Clinton's health care reform efforts. Negative changes in Medicare and Medicaid may be forthcoming, however. Companies with innovative drugs and extensive product lines will succeed in the 1990s.
Author: Cohen, David R., Butler, Jeremy J., Markey, Keith A., Malhotra, Vik, Ferguson, Keith E., Rho, George I.H., Byrne, Andrew J.
Publisher: Value Line Publishing, Inc.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 1995
Pharmaceutical Preparations, CYGN, Genetics Institute Inc., GENI, MKC, Hoechst Marion Roussel Inc., Upjohn Co., Cygnus Therapeutic Systems, MYL, PRR
Subjects list: Economic aspects, Pharmaceutical industry, Drugs, Finance, Eli Lilly and Co., Pfizer Inc., Glaxo Wellcome PLC, Genentech Inc., Warner-Lambert Co., Biogen Inc., Bristol-Myers Squibb Co., ALZA Corp., Amgen Inc., Chiron Corp., Forest Laboratories Inc., Genzyme Corp., Immunex Corp., IVAX Corp., Mylan Laboratories Inc., Perrigo Co., Schering-Plough Corp., Sicor Inc., AZA, AHP, BGEN, BMY, CHIR, FRX, GENZ, ICN, IMNX, IVX, LLY, PFE, SGP, WLA, GNE, Valeant Pharmaceuticals International, Wyeth, Merck & Company Inc., Rhone-Poulenc Rorer Inc., Roberts Pharmaceutical Corp., RPCX, R.P. Scherer Corp., RPR
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
